Table 2.
Outcomes of randomized Phase II trials comparing concurrent chemo-RT to RT alone
| Study (authors or trial) | Median follow-up (months) | Time point (years) | Treatment arm | OS (%) | PFS (%) | DMFS (%) | Ref |
|---|---|---|---|---|---|---|---|
| Al-Sarraf et al (USA) | 60 | 5 | RT | 37 | 29 | 1 | |
| Chemo-RT | 67 | 58 | |||||
| P = 0.001 | P < 0.001 | ||||||
| Chan et al (Hong Kong) | 66 | 5 | RT | 80 | 52 | 11 | |
| Chemo-RT | 90 | 60 | |||||
| P = 0.049 | P = 0.16 | ||||||
| Lin et al (Taiwan) | 65 | 5 | RT | 54 | 53 | 70 | 5 |
| Chemo-RT | 72 | 72 | 79 | ||||
| P = 0.002 | P = 0.001 | P = 0.058 | |||||
| Kwong et al (Hong Kong) | 37 | 3 | RT | 77 | 58 | 71 | 4 |
| Chemo-RT | 87 | 69 | 85 | ||||
| P = 0.06 | P = 0.14 | P = 0.026 | |||||
| Zhang et al (Guangzhou) | 24 | 2 | RT | 77 | 83 | 80 | |
| Chemo-RT | 100 | 96 | 92 | 70 | |||
| P = 0.01 | P = 0.02 | P = 0.02 | |||||
| Wee et al (Singapore) | 38 | 2 | RT | 49 | 46 | 3 | |
| Chemo-RT | 67 | 59 | |||||
| P = 0.008 | P = 0.032 | ||||||
| Lee et al (Hong Kong) | 25 | 3 | RT | 78 | 62 | 73 | |
| Chemo-RT | 78 | 72 | 76 | 2 | |||
| P = 0.97 | P = 0.027 | P = 0.47 | |||||
| Lee et al (Hong Kong) | 35 | 3 | RT | 83 | 68 | 81 | |
| Chemo-RT | 87 | 73 | 89 | ||||
| A-RT | 73 | 63 | 77 | ||||
| Chemo-A-RT | 88 | 88 | 97 | 13 | |||
| P = 0.65 | P = 0.061 | P = 0.029 | |||||
| Chen et al (Guangzhou) | 29 | 2 | RT | 80 | 73 | 79 | |
| Chemo-RT | 90 | 85 | 87 | 14 | |||
| P = 0.003 | P = 0.001 | P = 0.024 |
Abbreviations: A-RT, accelerated radiotherapy; DMFS, distant metastases-free survival; OS, overall survival; PFS, progression-free survival; RT, radiotherapy.